MN Services Vermogensbeheer
PFE icon

MN Services Vermogensbeheer’s Pfizer PFE Stock Holding History

MN Services Vermogensbeheer’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$48.2M Buy
1,689,911
+32,500
+2% +$864K 0.36% 60
2026
Q2 		$39.9M Sell
1,657,411
-536,600
-24% -$14M 0.3% 67
2026
Q1 		$61.6M Sell
2,194,011
-2,600
-0.1% -$69.2K 0.41% 49
2025
Q4 		$54.7M Buy
2,196,611
+37,611
+2% +$948K 0.34% 63
2025
Q3 		$55M Buy
2,159,000
+38,800
+2% +$958K 0.36% 61
2025
Q2 		$51.4M Buy
2,120,200
+51,900
+3% +$1.21M 0.36% 60
2025
Q1 		$52.4M Sell
2,068,300
-162,000
-7% -$4.24M 0.41% 52
2024
Q4 		$59.2M Buy
2,230,300
+46,200
+2% +$1.25M 0.4% 50
2024
Q3 		$63.2M Sell
2,184,100
-47,800
-2% -$1.39M 0.44% 48
2024
Q2 		$62.4M Sell
2,231,900
-50,900
-2% -$1.4M 0.45% 44
2024
Q1 		$63.3M Sell
2,282,800
-385,500
-14% -$10.7M 0.46% 45
2023
Q4 		$76.8M Sell
2,668,300
-85,800
-3% -$2.59M 0.69% 33
2023
Q3 		$91.4M Buy
2,754,100
+57,400
+2% +$2.03M 0.88% 24
2023
Q2 		$98.9M Buy
+2,696,700
New +$105M 0.92% 22
2019
Q3 		– Sell
-1,002,761
Closed -$41.2M – 542
2019
Q2 		$41.2M Sell
1,002,761
-44,900
-4% -$1.78M 0.48% 45
2019
Q1 		$42.2M Sell
1,047,661
-4,849
-0.5% -$194K 0.49% 49
2018
Q4 		$38.1M Buy
1,052,510
+63,240
+6% +$2.63M 0.58% 42
2018
Q3 		$41.4M Sell
989,270
-8,748
-0.9% -$337K 0.97% 13
2018
Q2 		$34.4M Buy
998,018
+9,908
+1% +$339K 0.86% 19
2018
Q1 		$33.3M Buy
988,110
+9,486
+1% +$326K 0.87% 18
2017
Q4 		$28M Sell
978,624
-58,708
-6% -$2M 0.88% 19
2017
Q3 		$35.1M Buy
1,037,332
+12,715
+1% +$409K 0.92% 16
2017
Q2 		$32.7M Buy
1,024,617
+853,670
+499% +$26.9M 0.9% 16
2017
Q1 		$5.19M Buy
170,947
+4,740
+3% +$149K 1% 15
2016
Q4 		$4.86M Buy
166,207
+837
+0.5% +$25.6K 0.99% 18
2016
Q3 		$5.31M Buy
165,370
+218
+0.1% +$7.29K 1.06% 15
2016
Q2 		$4.97M Buy
165,152
+2,057
+1% +$65.6K 1.15% 13
2016
Q1 		$4.02M Buy
+163,095
New +$4.66M 0.94% 16

Other funds holding PFE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Willis Investment Counsel
Willis Investment Counsel Gainesville, Georgia $1.97B AUM 25.29% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Kepler Cheuvreux
Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

MN Services Vermogensbeheer's PFE Position: Q3 2026 in Review

MN Services Vermogensbeheer increased its Pfizer (PFE) stake by 2% in Q3 2026, buying an estimated $864K and bringing the position to 1,689,911 shares worth $48.2M. The position accounts for 0.36% of the portfolio, ranked #60.

MN Services Vermogensbeheer first reported a position in PFE in Q1 2016 and has held it in 28 quarters since. The position peaked at $98.9M in Q2 2023. 616 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • MN Services Vermogensbeheer held 1,689,911 shares of Pfizer worth $48.2M as of Q3 2026.
  • MN Services Vermogensbeheer bought 32,500 Pfizer shares in Q3 2026, an estimated $864K.
  • Pfizer made up 0.36% of MN Services Vermogensbeheer's portfolio in Q3 2026, its #60 holding.
  • MN Services Vermogensbeheer first reported a position in Pfizer in Q1 2016 and has held it in 28 quarters since.
  • MN Services Vermogensbeheer's Pfizer position peaked at $98.9M in Q2 2023.
  • 616 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on MN Services Vermogensbeheer's 13F filing for Q3 2026, filed 8 Oct 2026.